Tissue Regenix Group PLC
LSE:TRX
Tissue Regenix Group PLC
Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. The company is headquartered in Leeds, West Yorkshire and currently employs 79 full-time employees. The company went IPO on 2006-12-21. The firm is focused on the development of regenerative products using its two platform technologies: decellularization (dCELL), which is used to produce allograft (DermaPure) and xenograft (OrthoPure XT) soft tissue products to promote healing and regeneration, and BioRinse, which is a natural bone filler solution verified to be osteoinductive to stimulate and regenerate native bone growth. The firm is engaged in transforming the treatment of patients in surgical applications, including BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology and Cardiac.
Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. The company is headquartered in Leeds, West Yorkshire and currently employs 79 full-time employees. The company went IPO on 2006-12-21. The firm is focused on the development of regenerative products using its two platform technologies: decellularization (dCELL), which is used to produce allograft (DermaPure) and xenograft (OrthoPure XT) soft tissue products to promote healing and regeneration, and BioRinse, which is a natural bone filler solution verified to be osteoinductive to stimulate and regenerate native bone growth. The firm is engaged in transforming the treatment of patients in surgical applications, including BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology and Cardiac.
Revenue Decline: Tissue Regenix reported a 6% drop in group revenue for H1 2025 compared to H1 2024, with softness seen in both the BioRinse and dCELL businesses.
Margin Pressure: Gross profit margin fell to 42%, impacted by higher inventory costs and lower production yields.
Cost Review: Management is conducting a comprehensive cost structure review and expects to announce results in the coming weeks, aiming to support near-term performance and long-term growth.
Regulatory Delays: The company was hit by significant regulatory delays for Certificates to Foreign Governments (CFGs), particularly affecting RDT exports and causing a 45% year-on-year decline in that segment.
Board & Strategy Shift: A new Board and Executive Chairman have been appointed, with a stronger focus on commercial execution and cost discipline.
Clinical Data Investment: Management emphasized the need for more clinical trials and publications to drive product adoption, stating clinical evidence is essential for commercial success.
Outlook: The company expects regulatory headwinds to persist but plans to focus resources on areas and geographies with the best opportunities for growth.
